WallStSmart

Merck & Company Inc (MRK)vsPennant Group Inc (PNTG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 5942% more annual revenue ($66.57B vs $1.10B). MRK leads profitability with a 4.8% profit margin vs 2.9%. PNTG appears more attractively valued with a PEG of 1.90. PNTG earns a higher WallStSmart Score of 59/100 (C).

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

PNTG

Buy

59

out of 100

Grade: C

Growth: 9.3Profit: 5.5Value: 4.3Quality: 4.0
Piotroski: 1/9Altman Z: 1.69
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$82.84

Current Price

$143.93

$61.09 premium

UndervaluedFair: $82.84Overvalued

Intrinsic value data unavailable for PNTG.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

PNTG2 strengths · Avg: 9.0/10
Revenue GrowthGrowth
35.8%10/10

Revenue surging 35.8% year-over-year

EPS GrowthGrowth
25.0%8/10

Earnings expanding 25.0% YoY

Areas to Watch

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

PNTG4 concerns · Avg: 3.5/10
PEG RatioValuation
1.904/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.694/10

Distress zone — elevated risk

Market CapQuality
$1.33B3/10

Smaller company, higher risk/reward

Profit MarginProfitability
2.9%3/10

2.9% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bull Case : PNTG

The strongest argument for PNTG centers on Revenue Growth, EPS Growth. Revenue growth of 35.8% demonstrates continued momentum.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Bear Case : PNTG

The primary concerns for PNTG are PEG Ratio, Altman Z-Score, Market Cap. A P/E of 42.2x leaves little room for execution misses. Thin 2.9% margins leave little buffer for downturns.

Key Dynamics to Monitor

MRK profiles as a value stock while PNTG is a hypergrowth play — different risk/reward profiles.

PNTG carries more volatility with a beta of 1.27 — expect wider price swings.

PNTG is growing revenue faster at 35.8% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

PNTG scores higher overall (59/100 vs 36/100) and 35.8% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Pennant Group Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

The Pennant Group, Inc. provides health care services in Arizona, California, Colorado, Idaho, Iowa, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The company is headquartered in Eagle, Idaho.

Want to dig deeper into these stocks?